Efficacy and Safety of 225Ac-PSMA-617-Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
出版年份 2022 全文链接
标题
Efficacy and Safety of 225Ac-PSMA-617-Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
作者
关键词
-
出版物
Frontiers in Oncology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-02-03
DOI
10.3389/fonc.2022.796657
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy
- (2021) Maarten J. van der Doelen et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer
- (2021) Danielle Meyrick et al. Targeted Oncology
- Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020
- (2021) Wei Cao et al. CHINESE MEDICAL JOURNAL
- Corrigendum to “French ccAFU guidelines–update 2020–2022: Prostate cancer” [Prog. Urol 30 (12 S) (2020), pp S136-S251]
- (2021) F. Rozet et al. PROGRES EN UROLOGIE
- Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
- (2021) Florian Rosar et al. Pharmaceutics
- Therapeutic efficacy of 225Ac-PSMA-617 targeted alpha therapy in patients of metastatic castrate resistant prostate cancer after taxane-based chemotherapy
- (2021) Ishita Sen et al. ANNALS OF NUCLEAR MEDICINE
- Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
- (2021) Oliver Sartor et al. NEW ENGLAND JOURNAL OF MEDICINE
- 177Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
- (2021) Finn E. von Eyben et al. Biomedicines
- Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2020) C. Parker et al. ANNALS OF ONCOLOGY
- Prostate-specific membrane antigen theranostics in advanced prostate cancer: an evolving option
- (2020) Nikhil Mayor et al. BJU INTERNATIONAL
- First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings
- (2020) Matteo Ferro et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA
- (2020) Benedikt Feuerecker et al. EUROPEAN UROLOGY
- PREDICTORS OF OVERALL AND DISEASE FREE SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS RECEIVING 225Ac-PSMA-617 RADIOLIGAND THERAPY
- (2019) Mike Sathekge et al. JOURNAL OF NUCLEAR MEDICINE
- Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions
- (2019) Roberto Iacovelli et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
- (2019) Fadi Khreish et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer
- (2018) Ali Afshar-Oromieh et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies—Part 1
- (2018) Sophie Poty et al. JOURNAL OF NUCLEAR MEDICINE
- Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
- (2018) Clemens Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
- (2018) Mike Sathekge et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy
- (2017) Anna Katharina Seitz et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding
- (2017) Clemens Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- (2016) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
- (2016) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- 225Ac-PSMA-617 for PSMA-Targeted -Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
- (2016) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- Efficient assessment of the most important symptoms in advanced prostate cancer: the NCCN/FACT-P Symptom Index
- (2010) David E. Victorson et al. PSYCHO-ONCOLOGY
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More